Showing 6,541 - 6,560 results of 18,262 for search 'significantly ((((linear decrease) OR (((we decrease) OR (a decrease))))) OR (larger decrease))', query time: 0.56s Refine Results
  1. 6541
  2. 6542

    Table_1_A causal association between obesity and constipation: a two-sample bidirectional Mendelian randomization study and meta-analysis.XLSX by Xian Sun (655494)

    Published 2024
    “…Therefore, we conducted a Mendelian randomization (MR) study and meta-analysis to assess the causal relationship between obesity and the risk of constipation.…”
  3. 6543

    Assembly error angle of a single spline. by Zhe Hu (787283)

    Published 2025
    “…Following model updates with measured data, the accumulated prediction error rapidly decreases. The proposed prediction method for shape errors during pushing exhibits high accuracy and versatility in similar projects, significantly reducing time spent on manual error handling and minimizing computational inaccuracies.…”
  4. 6544
  5. 6545
  6. 6546
  7. 6547
  8. 6548
  9. 6549
  10. 6550
  11. 6551
  12. 6552

    Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  13. 6553

    Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  14. 6554

    Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  15. 6555

    Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  16. 6556

    Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  17. 6557
  18. 6558
  19. 6559
  20. 6560